Cogent Biosciences Announces Positive Updated Clinical Data from Ongoing Phase 2 APEX…
- 89% ORR in TKI-therapy naïve patients; 73% ORR in all evaluable patients with 27-week median follow-up - Rapid and deep responses seen including first confirmed CR at 20 weeks; 77%…